In one study, they showed that the CD44 3′UTR serves as a competitor for hsa-miR-216a-5p, hsa-miR-330-3p, and and hsa-miR-608 to increase CD44 and CDC42 protein levels in the breast cancer cell line MT-1, resulting in inhibition of cell proliferation and tumor-formation, promotion of angiogenesis, and induction of apoptosis [39]. The gene discussed is CD44; the disease is breast cancer.